¡Ya estamos en ! Descubre más

IQVIA

IQV

Capitalización de mercado USD 43.9 mil M

266.90 USD

-4.14

1.53%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

266.90

0.00

0%

1 día

-1.53%

5 días

2.56%

1 mes

-0.71%

3 meses

26.8%

6 meses

55.22%

En lo que va del año

18.43%

1 año

29.72%

5 años

7.42%

10 años

254.54%

Acerca de: Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

Empleados: 94,000

Atención médica Diagnósticos e investigación

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 56.8%

Neutral 35.1%

Negativo 8.1%

IQVIA Selects Veeva Clinical Operations Applications

RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif.

IQVIA Selects Veeva Clinical Operations Applications

Zacks Investment Research

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes. IQVIA Life Science Models are a suite of purpose-built models for life sciences, combining IQVIA's proprietary expert content, deep domain knowledge and established regulatory, com.

IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Explorer™ to help customers make better-informed commercial decisions. IQVIA Explorer turns complex, one-time analytics projects into an always-on commercial intelligence capability. Users can apply external indicators and ask business questio.

IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions

Zacks Investment Research

Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.

Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanyin.

IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026

Zacks Investment Research

IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.

IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

Zacks Investment Research

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

IQVIA Announces Pricing of Senior Notes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and e.

IQVIA Announces Pricing of Senior Notes

IQVIA Announces Offering of Senior Notes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and expenses relate.

IQVIA Announces Offering of Senior Notes

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™